Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proceedings of the National Academy of Sciences of the United States of America Sagiv-Barfi, I., Kohrt, H. E., Czerwinski, D. K., Ng, P. P., Chang, B. Y., Levy, R. 2015; 112 (9): E966-72

View details for DOI 10.1073/pnas.1500712112

View details for PubMedID 25730880